Onglyza®, the brand name for saxagliptin, is a prescription medication used to treat Type 2 Diabetes. It was approved by the U.S. Food and Drug Administration in July 2009. Onglyza® belongs to a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 is an enzyme that breaks down incretin hormones. As a DPP-4 inhibitor, Onglyza® slows down the breakdown of incretin hormones by the body, thereby increasing the levels of these hormones in the body. The resulting increased blood levels of incretin hormones are responsible for the beneficial actions of Onglyza®, increased insulin production in response to eating meals and the decrease of the rate glucose is produced by the liver.
Onglyza® Heart Failure Risks
In October 2013, a study published in the New England Journal of Medicine showed that patients taking Onglyza® were more likely than those taking other Type 2 Diabetes drugs to develop heart failure. As a result of the publication of this study, the Food and Drug Administration (FDA) launched an investigation into the correlation between Onglyza® use and heart failure. In April 2015, the FDA published briefing materials from its Endocrinologic and Metabolic Drugs Advisory Committee Meeting. The briefing materials show that there were a significant number of first-time heart failure hospitalizations in patients taking Onglyza®. These findings prompted the manufacturer of Onglyza® to update the drug’s warning label to include a warning about the increased risk of development of heart failure in patients taking Onglyza®.
Our Lawyers are Here to Help You
The attorneys at Franklin D. Azar and Associates are experienced in handling pharmaceutical cases from start to finish. We are here to help you if you have been wrongfully injured by a pharmaceutical drug like Onglyza®. Our attorneys are standing by to help you in your times of need. Call us today for a free consultation.